ANN ARBOR, Mich., March 15, 2005 (PRIMEZONE) -- MIR Preclinical Services (MIR) is pleased to announce the acceptance of the following findings at the upcoming annual meeting of the American Association for Cancer Research (AACR), April 16-20 in Anaheim, California. These studies highlight some of the advances MIR is making in the fields of preclinical cancer drug evaluation and molecular imaging. The titles and authors of the presentations are as follows:
1. MRI predicts tumor grade and survival in a tv-a transgenic model of
glioma. Jonathan B. Moody, et al. Abstract number: 1068; Poster
Session ID: Tumor Biology 6, presented April 17th at 1:00 PM.
2. Evaluation of MRI in a mouse model of liver metastasis. Alicia
R.Kreger, et al. Abstract number: 3794; Poster Session ID: Tumor
Biology 25, presented April 19th at 8:00 AM.
3. MRI determination of Temozolomide treatment response in a
tv-atransgenic model of glioma. Patrick McConville, et al. Abstract
number: 3787; Poster Session ID: Tumor Biology 25, presented April
19th at 8:00AM.
4. In vivo micro-CT of mouse lungs without respiratory gating.
ErinTrachet, et al. Abstract number: 3795; Poster Session ID:
Tumor Biology 25, presented April 19th at 8:00 AM.
5. In vivo imaging of a mouse model of PC-3 bone metastasis.
Jonathan B. Moody, et al. Abstract number: Poster Session ID:
Tumor Biology 25, presented April 19th at 8:00 AM.
"MIR is looking forward to presenting its innovative research at the AACR conference again this year," said Dr. Leopold, president of MIR. "An important part of our corporate mission is the creation and application of new technology that will better forecast the clinical potential of our clients' drug candidates. Our staff is working diligently to improve the way cancer therapeutics are evaluated in preclinical development. These presentations reflect the fruits of that effort. Toward this goal, the company also actively collaborates with leading scientists in academia in developing new drug evaluation technologies and encourages the publication of the results in peer reviewed journals."
About MIR Preclinical Services
MIR is a Contract Research Organization specializing in the preclinical evaluation of novel anti-tumor agents. The company boasts management with over 60 years of major pharma cancer drug discovery experience, and is a leader in the integration of traditional anti-cancer efficacy testing with clinically relevant imaging technologies to provide new insights to drug discovery and development. MIR offers a wide array of tumor models including human tumor xenograft, syngeneic, and transgenic models. The company is unique in its ability to apply state-of-the-art non-invasive imaging modalities including magnetic resonance imaging (MRI), X-ray micro-CT, high resolution small animal PET and in vivo optical imaging to visualize biological processes such as signal transduction, apoptosis and angiogenesis.